Bibliography
- Hajhosseiny R, Khavandi K, Jivraj N, et al. Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs 2014;23(4):511-22
- Onuigbo MAC. Renoprotection and the bardoxolone methyl story - is this the right way forward? A novel view of renoprotection in CKD trials: a new classification scheme for renoprotective agents. Nephron Extra 2013;3:36-49
- Onuigbo MA. Reno-prevention versus renoprotection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET – a call for more circumspection. QJM 2009;102:155-67
- Onuigbo MA, Onuigbo N. Chronic kidney disease and RAAS blockade: a new view of renoprotection. Lambert Academic Publishing GmbH & Co. KG, London; 2011
- Onuigbo MA. Epilogue - bold predictions and the future of renoprotection: the way forward with multiple pathway blockers – making a case for novel non-angiotensin inhibiting renoprotective agents like corticotropin and pentoxifylline. In: Onuigbo MAC, editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 2. NOVA Publishers; New York, NY; 2013